| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,865 | 0,940 | 18.11. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MAAT PHARMA Aktie jetzt für 0€ handeln | |||||
| Mo | MaaT Pharma Reports Financial Results for the Third Quarter 2026 | 398 | Business Wire | Revenues of EUR 0.5 million in the third quarter of 2026 and EUR 1.6 million year-to-date, derived from the Early Access Program
As of September 30, 2026, cash and cash equivalents were... ► Artikel lesen | |
| 06.11. | MaaT Pharma Provides an Update on Preliminary Findings from the Investigator-Sponsored Phase 2a PICASSO Trial in Metastatic Melanoma | 376 | Business Wire | PICASSO, an investigator-sponsored study conducted by AP-HP in collaboration with INRAe and Gustave Roussy, evaluated the safety of adding MaaT013 (Xervyteg) to ipilimumab and nivolumab in patients... ► Artikel lesen | |
| 19.10. | MaaT Pharma Receives FDA Feedback Following Pre-IND Meeting Supporting Continued Development of MaaT034 in Solid Tumors | 456 | Business Wire | Positive pre-Investigational New Drug (pre-IND) interaction with the Food Drug Administration (FDA) on Chemistry, Manufacturing and Controls (CMC) and nonclinical topics supports MaaT034's continued... ► Artikel lesen | |
| 07.10. | Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): Under Review | 356 | EQS Group (EN) | Original-Research: MaaT Pharma SACA - from First Berlin Equity Research GmbH
07.10.2026 / 14:10 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| 29.09. | MaaT Pharma Publishes its Half-Year 2026 Results and Provides a Business Update | 632 | Business Wire | MaaT013 (Xervyteg):
In September 2026, following the re-examination procedure, the CHMP maintained its negative opinion on the Conditional Marketing Authorization Application (MAA) for... ► Artikel lesen | |
| 21.09. | MaaT Pharma Announces Upcoming Pre-IND Meeting with the FDA and Advances MaaT034 Toward Clinical Development in Solid Tumors | 543 | Business Wire | Pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA), focused on CMC (Chemistry, Manufacturing, and Controls), is scheduled for October 2026, representing... ► Artikel lesen | |
| 18.09. | MaaT Pharma Provides Update on MaaT013 (Xervyteg) Potential Development Plan Following CHMP Negative Opinion After Re-examination | 681 | Business Wire | The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the Company's application for a Conditional Marketing Authorization... ► Artikel lesen | |
| 15.09. | MaaT Pharma Receives Negative CHMP Trend Vote for MaaT013 (Xervyteg) Following Re-Examination for its Conditional Marketing Authorization Application in Europe | 548 | Business Wire | MaaT Pharma was informed of a negative trend during the Committee for Medicinal Products for Human Use (CHMP)'s Oral Explanation meeting which took place on September 14, 2026
Formal CHMP... ► Artikel lesen | |
| 06.07. | MaaT Pharma Presents the Results of its Annual General Meeting and Provides a Statement on its Half-Year Liquidity Contract | 439 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 02.07. | MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 516 | Business Wire | Article 223-16 of the General Regulations of the Financial Markets Authority
(AMF Autorité des Marchés Financiers)
Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage... ► Artikel lesen | |
| 30.06. | Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): Under review | 423 | EQS Group (EN) | Original-Research: MaaT Pharma SACA - from First Berlin Equity Research GmbH
30.06.2026 / 13:08 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| 26.06. | EMA committee issues negative opinion on MaaT Pharma's MaaT013 | 5 | Investing.com | ||
| 26.06. | MaaT Pharma Announces Plan to Request Re-Examination Following Negative CHMP Opinion for MaaT013 for the treatment of acute Graft-versus-Host Disease | 1.203 | Business Wire | The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the conditional Marketing Authorization Application (MAA) for MaaT013... ► Artikel lesen | |
| 11.06. | Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): Under review | 370 | EQS Group (EN) | Original-Research: MaaT Pharma SACA - from First Berlin Equity Research GmbH
11.06.2026 / 13:07 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| 26.05. | MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2026 | 1.048 | Business Wire | MaaT013 (Xervyteg):
In May 2026, the Company was informed of a "negative trend" opinion on its Marketing Authorization Application from the Committee for Medicinal Products for Human Use... ► Artikel lesen | |
| 20.05. | MaaT Pharma Provides an Update on the Application for Marketing Authorization of MaaT013 (Xervyteg) in the treatment of acute Graft-versus-Host Disease | 1.047 | Business Wire | During the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) Oral Explanation, the Company received a "negative trend" opinion for the upcoming June... ► Artikel lesen | |
| 11.05. | MaaT Pharma to Hold Annual General Meeting on June 16, 2026 | 489 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 21.04. | Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): Buy | 423 | EQS Group (EN) | Original-Research: MaaT Pharma SACA - from First Berlin Equity Research GmbH
21.04.2026 / 15:09 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| 01.04. | MaaT Pharma Announces Publication of Retrospective Data in Third-Line Acute GvHD from the CHRONOS Study in Bone Marrow Transplantation Journal | 622 | Business Wire | CHRONOS is one of the largest real-world studies including refractory GI-aGvHD patients (n=59) treated with third-line best available treatments other than microbiome-based therapy
Results... ► Artikel lesen | |
| 31.03. | MaaT Pharma Announces 2025 Annual Results and Provides Business Updates | 782 | Business Wire | Potential Pivotal Year for MaaT013 (Xervyteg):
Marketing Authorization Application (MAA) in Europe for MaaT013 (Xervyteg) submitted to the European Medicines Agency (EMA) in June 2025
... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 8,880 | -0,34 % | Intellia auf der Jefferies Global Healthcare Conference: Marktstart und Pipeline im Fokus | ||
| KUROS BIOSCIENCES | 21,000 | +0,96 % | Kuros Biosciences: Höhere Prognose - der Rebound bekommt Rückenwind | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,800 | +7,63 % | Pacific BioSciences of California (NDQ:PACB): After a Horror 2 Years, Is This Company About To Reach Its Inflection Point | ||
| MICROBOT MEDICAL | 0,634 | -3,94 % | Citizens lowers Microbot Medical stock price target on weak Q3 results | ||
| BEONE MEDICINES LTD ADR | 366,00 | -0,54 % | If You Invested $100 In BeOne Medicines Stock 10 Years Ago, You Would Have This Much Today | ||
| BIOMERIEUX | 90,45 | 0,00 % | Was der Markt bei bioMérieux übersah! | ||
| BIOXCEL THERAPEUTICS | 0,065 | 0,00 % | BioXcel Therapeutics, Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | ||
| PDS BIOTECHNOLOGY | 0,730 | +0,27 % | PDS Biotechnology GAAP EPS of -$0.11 misses by $0.02 | ||
| BIO GREEN MED SOLUTION | 0,583 | +1,43 % | Bio Green Med Solution declares $0.15 dividend | ||
| ANAPTYSBIO | 40,770 | -4,99 % | AnaptysBio GAAP EPS of $0.11 misses by $0.28, revenue of $30.27M misses by $3.19M | ||
| ZYMEWORKS | 23,870 | +0,55 % | Zymeworks authorizes up to $200M in share repurchases | ||
| GENUS | 27,000 | -1,46 % | Dividendenbekanntmachungen (12.11.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AEBI SCHMIDT HOLDING AG CH0027352993 0,025 USD 0,0225 EUR AIRTEL AFRICA PLC GB00BKDRYJ47 0,031 USD 0,0279 EUR ALLWYN AG GRS419003009 - ... ► Artikel lesen | |
| AKESO | 6,796 | +0,59 % | CMBI Cuts AKESO TP to HKD99.34; HARMONi-3 Remains Key Catalyst | ||
| MEIRAGTX | 8,150 | +7,95 % | MeiraGTx Announces Oral Presentation at ObesityWeek 2026 | ||
| ABIONYX PHARMA | 1,530 | 0,00 % | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | Article L233-8-II of the French Commercial Code
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market:... ► Artikel lesen |